$3.79
5.25% day before yesterday
Nasdaq, Dec 27, 10:10 pm CET
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

C4 Therapeutics Inc Stock price

$3.79
-0.76 16.70% 1M
-0.83 17.97% 6M
-1.86 32.92% YTD
-1.34 26.12% 1Y
-29.18 88.50% 3Y
-15.21 80.05% 5Y
-15.21 80.05% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.21 5.25%
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

Key metrics

Market capitalization $267.53m
Enterprise Value $78.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.35
P/S ratio (TTM) P/S ratio 7.95
P/B ratio (TTM) P/B ratio 1.10
Revenue growth (TTM) Revenue growth 65.45%
Revenue (TTM) Revenue $33.67m
EBIT (operating result TTM) EBIT $-116.90m
Free Cash Flow (TTM) Free Cash Flow $-71.58m
Cash position $255.64m
EPS (TTM) EPS $-1.70
P/E forward negative
P/S forward 7.47
EV/Sales forward 2.20
Short interest 15.22%
Show more

Is C4 Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

C4 Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a C4 Therapeutics Inc forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a C4 Therapeutics Inc forecast:

Buy
67%
Hold
33%

Financial data from C4 Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
34 34
65% 65%
100%
- Direct Costs 7.82 7.82
3% 3%
23%
26 26
111% 111%
77%
- Selling and Administrative Expenses 26 26
1% 1%
78%
- Research and Development Expense 109 109
8% 8%
322%
-109 -109
17% 17%
-324%
- Depreciation and Amortization 7.82 7.82
3% 3%
23%
EBIT (Operating Income) EBIT -117 -117
16% 16%
-347%
Net Profit -106 -106
22% 22%
-313%

In millions USD.

Don't miss a Thing! We will send you all news about C4 Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

C4 Therapeutics Inc Stock News

Neutral
GlobeNewsWire
21 days ago
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels
Neutral
GlobeNewsWire
about one month ago
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
Neutral
GlobeNewsWire
2 months ago
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock optio...
More C4 Therapeutics Inc News

Company Profile

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Hirsch
Employees 145
Founded 2015
Website www.c4therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today